Addison Capital Co Has $2.57 Million Position in Allergan PLC. (AGN)

Addison Capital Co increased its stake in shares of Allergan PLC. (NYSE:AGN) by 3.1% during the second quarter, Holdings Channel reports. The institutional investor owned 10,561 shares of the company’s stock after buying an additional 319 shares during the period. Allergan PLC. accounts for approximately 2.1% of Addison Capital Co’s portfolio, making the stock its 14th largest position. Addison Capital Co’s holdings in Allergan PLC. were worth $2,567,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Crestwood Advisors Group LLC bought a new stake in shares of Allergan PLC. during the first quarter valued at approximately $103,000. Feltz Wealth PLAN Inc. bought a new stake in shares of Allergan PLC. during the first quarter valued at approximately $107,000. Enterprise Financial Services Corp increased its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC increased its stake in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors increased its stake in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Get Allergan PLC. alerts:

Shares of Allergan PLC. (NYSE:AGN) traded down 0.47% on Thursday, hitting $226.91. The stock had a trading volume of 1,023,430 shares. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The stock has a market capitalization of $75.86 billion, a PE ratio of 6.91 and a beta of 1.16. The firm’s 50 day moving average is $244.51 and its 200-day moving average is $238.70.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the company posted $3.35 earnings per share. Allergan PLC.’s revenue was up 8.8% on a year-over-year basis. Equities research analysts expect that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.23%. Allergan PLC.’s payout ratio is presently 9.95%.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/17/addison-capital-co-has-2-57-million-position-in-allergan-plc-agn.html.

Several brokerages have recently commented on AGN. UBS AG reaffirmed a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a report on Monday, May 15th. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a report on Monday, June 26th. Royal Bank Of Canada set a $284.00 target price on Allergan PLC. and gave the company a “buy” rating in a report on Monday, June 12th. BidaskClub raised Allergan PLC. from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Finally, Mizuho reaffirmed a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).